Dr. Ania M. Jastreboff
Yale University School
Biography & Research Background
Ania M. Jastreboff, MD, PhD, is an Associate Professor at Yale University School of Medicine (New Haven, CT, USA) and Director of the Yale Obesity Research Center. She served as the lead investigator for the pivotal Phase 2 clinical trial evaluating retatrutide for the treatment of obesity, published in the New England Journal of Medicine in 2023. Her work demonstrated that the drug could achieve up to 24.2% mean body weight reduction over 48 weeks, establishing retatrutide as one of the most potent investigational anti-obesity agents. Dr. Jastreboff is recognized as a leading clinical researcher in the incretin-based obesity therapeutics field, having also led pivotal trials for tirzepatide and other novel agents. Her key publications include "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial" (2023, New England Journal of Medicine). Ania M. Jastreboff is being referenced as one of the leading scientists involved in retatrutide research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (2)
Dr. Ania M. Jastreboff is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Ania M. Jastreboff is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.